ID: ALA5196817

Max Phase: Preclinical

Molecular Formula: C23H24ClN7O

Molecular Weight: 449.95

Representations

Canonical SMILES:  CCCCNc1nc(Cl)nc2c1ncn2Cc1ccc(C(=O)Nc2ccccc2N)cc1

Standard InChI:  InChI=1S/C23H24ClN7O/c1-2-3-12-26-20-19-21(30-23(24)29-20)31(14-27-19)13-15-8-10-16(11-9-15)22(32)28-18-7-5-4-6-17(18)25/h4-11,14H,2-3,12-13,25H2,1H3,(H,28,32)(H,26,29,30)

Standard InChI Key:  UTSVDUQIDLMZLA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 449.95

Molecular Weight (Monoisotopic): 449.1731

AlogP: 4.57

#Rotatable Bonds: 8

Polar Surface Area: 110.75

Molecular Species: NEUTRAL

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 3.28

CX LogP: 4.21

CX LogD: 4.21

Aromatic Rings: 4

Heavy Atoms: 32

QED Weighted: 0.21

Np Likeness Score: -1.28

References

1. Mao PT, He WB, Mai X, Feng LH, Li N, Liao YJ, Zhu CS, Li J, Chen T, Liu SH, Zhang QM, He L..  (2022)  Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.,  56  [PMID:35041998] [10.1016/j.bmc.2021.116599]

Source

Source(1):

• Scientific Literature